COVID-19 Impacts Cancer Care & Hospitalizations
Understanding the Heightened Vulnerability
The COVID-19 pandemic has presented unique challenges for individuals battling cancer. Emerging research underscores that patients with cancer face a significantly elevated risk of severe COVID-19 outcomes, including hospitalization and even death. This heightened vulnerability is a critical concern for healthcare providers, especially pharmacists, who play a pivotal role in patient care and education.
Key Risk Factors Identified
A prospective cohort study, the National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS), has shed further light on the specific factors that increase COVID-19 severity in this population. the study authors confirmed and expanded upon previous findings, identifying several key risk factors. These include:
Hematologic Cancers: Patients with blood cancers appear to be at a greater risk of severe COVID-19.
Chemotherapy Receipt: Individuals currently undergoing chemotherapy treatment are also more susceptible to adverse outcomes.
Lung Cancer: Patients diagnosed with lung cancer have demonstrated a higher risk of severe COVID-19.
As SARS-CoV-2 transitions from a pandemic to an endemic illness,it is imperative that populations identified as being at extreme risk continue to be closely monitored and supported.
The Pharmacist’s Essential Guidance and Support
Pharmacists are uniquely positioned to provide crucial guidance and support to patients with cancer navigating the complexities of COVID-19. Their expertise in medication management and patient counseling makes them invaluable allies in protecting this vulnerable group.
Proactive Protection and Vaccination
Pharmacists should proactively counsel patients with cancer, especially those actively undergoing treatment, about their increased risks and their responsibilities in staying protected. A cornerstone of this protection is the COVID-19 vaccine. Pharmacists can:
Educate on Vaccine Efficacy: Explain the importance of vaccination in reducing the risk of severe illness, hospitalization, and death.
Address Vaccine Hesitancy: Provide accurate information and address any concerns or misconceptions patients may have regarding COVID-19 vaccines, particularly in the context of their cancer treatment.
Facilitate Access: Assist patients in accessing vaccination services and scheduling appointments.
Minimizing Treatment Disruptions
Beyond the direct health risks of COVID-19 infection, the impact of treatment disruptions on patients with cancer is a significant concern. Research has highlighted the potential for COVID-19 to interfere with essential cancer therapies. Pharmacists have a critical responsibility to:
Ensure Treatment Continuity: To the best of their ability, pharmacists should work to ensure that patients with cancer who contract COVID-19 do not experience any delays in their ongoing cancer treatment. This may involve close communication with oncologists and other healthcare providers.
Aid in Management: Educate and assist patients on how to effectively manage both their cancer treatment and their COVID-19 illness concurrently. This includes advising on potential drug interactions, symptom management, and when to seek further medical attention.
Looking Ahead: Continued Vigilance and research
The ongoing transition of SARS-CoV-2 to an endemic state necessitates continued vigilance and research. The findings from studies like NCCAPS are vital in shaping clinical practice and public health strategies. Pharmacists, as accessible and trusted healthcare professionals, will continue to play a critical role in safeguarding the health and well-being of patients with cancer throughout this evolving landscape.By staying informed, providing expert counsel, and advocating for uninterrupted care, pharmacists can significantly mitigate the risks associated with COVID-19 for this vulnerable patient population.
References
- Rini BI, Best AF, Bowman MD, et al. Risk Factors for COVID-19-Related Hospitalization and Death in Patients With Cancer: The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS). JAMA Oncol. 2025. Published Online July 17,2025. doi:10.1001/jamaoncol.2025.2010
- Zhang Ji, Dong X, Liu G, et al.Risk and Protective Factors for COVID-19 Morbidity, Severity, and mortality.Clinic Rev Allerg Immunol. 2023; 64: 90-107.Two: 10.1007/S12016-022-089